focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksConcurrent Technologies Regulatory News (CNC)

Share Price Information for Concurrent Technologies (CNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 101.50
Bid: 100.00
Ask: 103.00
Change: 2.50 (2.53%)
Spread: 3.00 (3.00%)
Open: 99.00
High: 101.50
Low: 99.00
Prev. Close: 99.00
CNC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Final Results

25 Mar 2014 07:00

RNS Number : 0507D
Concurrent Technologies PLC
25 March 2014
 



25 March 2014

Concurrent Technologies Plc

Preliminary Results for the year ended 31 December 2013

 

Concurrent Technologies Plc (the "Company"), a world leading specialist in the design and manufacture of high-end embedded computer products, for critical applications in the defence, aerospace, transportation, telecommunications, scientific and industrial markets, announces preliminary results for the year to 31 December 2013.

 

Financial Highlights

 

· Turnover £11.9m (2012: £12.8m)

· EBITDA £1.9m (2012: £3.5m)

· Profit before Tax £0.5m (2012: £2.0m)

· Cash in business plus deposits increased to £4.9m (2012: £4.3m)

· EPS 1.02 pence (2012: 2.75 pence)

· Dividend increased by 2.94% to 1.75 pence per share for the year (2012: 1.70 pence)

 

Operational Highlights

 

· 7 new high performance processor boards released, featuring the latest technology including 4th generation Intel® Core™ processors and new Intel® Atom™ processors.

· Additional development of software and middleware to provide high technology intercommunication and security.

· Improvement in sales to defence customers despite setbacks due to export licencing requirements.

· Further significant growth in sales of product using AMC architecture in telecoms.

· Continued improvement in VPX™ architecture product sales mainly for defence applications.

 

Michael Collins, Chairman, commented:

 

"Against a challenging export environment, we have delivered another year of profitability. Our objective remains to design more innovative products for complex, high technology, low to medium volume and high margin applications, including versions for use in harsh environments. We also aim to further enhance the capabilities of these products with new and complementary software packages to provide high-speed data transfer, ease of integration and security. We will continue to be an early adopter of the latest technology from Intel and maintain our investment in R&D to ensure an expansion of our range of advanced technology products. To augment our R&D capabilities and to complement our UK and Indian design centres, we intend to establish an R&D facility in Massachusetts, USA."

"We know that our diverse product range and the continuing investment in applying new technology to our product ranges enhances the Group's position in a variety of different markets. The probable improvement in the situation regarding export licence restrictions is also expected to improve the Group's prospects during 2014."

 

Annual General Meeting

 

The annual general meeting of Concurrent Technologies Plc will be held at the Company's offices at 4 Gilberd Court, Newcomen Way, Colchester, Essex, CO4 9WN, on 27 May 2014 at 2:30pm.

 

Enquiries:

 

Concurrent Technologies PlcGlen Fawcett, Managing Director

 

+44 (0)1206 752 626

Newgate Threadneedle (Financial PR)Caroline Forde

Robyn McConnachie

+44 (0)207 653 9850

Cenkos Securities plc (NOMAD)Neil McDonald

Beth McKiernan

+44 (0)131 220 9771+44 (0)131 220 9778

Extracts from the Strategic Report

Review of Operations

As announced prior to the last Interim Results, one of the main challenges during this year has been the problem of the licencing of advanced technology exports to emerging markets where we were expecting sales growth. These exporting issues have been raised with the Secretary of State for Business, Innovation and Skills (BIS). The Company continues to work with BIS officials who are reviewing the current system of control to determine whether the affected products may be moved to a more flexible export licensing system such as that which exists in the USA.

These export licencing issues have had a negative impact on the results for the year and may continue to adversely affect trading relationships with some of our customers. However, although the report on the review by BIS was delayed, due to critical world events, we have made good progress and the Board is optimistic that the more flexible licensing system that we need from BIS will be introduced by the end of June 2014.

The results for this year include a write down of our R&D design assets by £842,783 (original estimate £1.3m), substantially due to the effects on possible future orders caused by UK export licencing.

The Group EBITDA (measured as Operating Profit plus Depreciation and Amortisation) for 2013 was £1,920,585 (2012: £3,479,094). The reduction was due to the lower level of sales, less capitalisation and increased impairments of R&D, compared to 2012, due to the export issues noted above. The Group achieved a profit before tax for 2013 of £453,929 (2012: £2,001,404), which includes the increased amortisation of capitalised R&D, a result which is slightly ahead of consensus forecasts. Earnings per share for the year were 1.02 pence (2012: 2.75 pence). Group revenue for the year was £11,859,180 (2012: £12,794,380). The gross margin for the year was 50.6% compared with 51.7% for 2012.

Our balance sheet remains strong due to underlying profitability and robust financial controls within the business, and our cash balances have been maintained despite the reduction in reported profit. We have also continued our investment in R&D and have increased our dividend compared to the previous year. We had cash balances of £2.3m (2012: £2.3m) plus short to medium term cash deposits of £2.6m (2012: £2.0m) at the year end, with no borrowings.

Operational Highlights

A critical element of our strategy is to maintain our investment in R&D to ensure a constant expansion of our product range in order to create new opportunities, protect our competitive position and provide our existing customers with viable technical upgrade paths. The investment in R&D was maintained throughout 2013.

A total of 7 new high performance embedded computers were released during the year, featuring the latest technology including 4th generation Intel® Core™ processors and new low power Intel® Atom™ processors. We have concentrated on providing more AMC and VPX™ architecture products, these usually being the architectures of choice for new projects and therefore offering greater potential for growth. Combined with a Serial RapidIO® interface, the AMC architecture products are particularly well suited for MicroTCA™ and AdvancedTCA® based telecommunications applications such as IPTV, digital media servers, media gateways, broadband, and Long Term Evolution (LTE) or LTE-Advanced, wireless base stations. They are also being utilised in test systems for wireline and wireless networks, where a large number of computing nodes are required to intercommunicate at very fast data transfer rates. Sales of our AMC boards have significantly increased during 2013. Our VPX™ architecture boards are mainly used in defence and surveillance related applications, including unmanned vehicles, and these have also shown continuing growth in sales during 2013.

To enhance the functionality of our hardware products, we have continued the development of key software projects. These include our Fabric Interconnect Networking Software for inter-board communications, and our Board Level Security Package, designed to assist customers to deliver secure solutions for applications where protecting critical technologies and data is essential.

The Group's customer base is well diversified comprising many large, high quality, international businesses, which use our products in many different applications. Sales for defence applications increased slightly during 2013 from the previous year and may have been even better if we had not been affected by the difficulties with export licencing. There were also increased sales for industrial applications, and also for scientific applications like physics research.

Future Plans

Against a challenging export environment, we have delivered another year of profitability. Our objective remains to design more innovative products for complex, high technology, low to medium volume and high margin applications, including versions for use in harsh environments. We also aim to further enhance the capabilities of these products with new and complementary software packages to provide high-speed data transfer, ease of integration and security. We will continue to be an early adopter of the latest technology from Intel and maintain our investment in R&D to ensure an expansion of our range of advanced technology products. To augment our R&D capabilities and to complement our UK and Indian design centres, we intend to establish an R&D facility in Massachusetts, USA.

We know that our diverse product range and the continuing investment in applying new technology to our product ranges enhances the Group's position in a variety of different markets. The probable improvement in the situation regarding export licence restrictions is also expected to improve the Group's prospects during 2014.

Dividend

The Board has declared a second interim dividend of 1.10 pence per share (2012: 1.05 pence second interim dividend) which when added to the first interim dividend of 0.65 pence per share will make a total of 1.75 pence per share for the year (2012: 1.70 pence). This is an increase of 2.94% on dividends paid for 2012. The total cost of this second interim dividend will amount to £785,405. The Directors do not intend to recommend a final dividend.

Annual General Meeting

The annual general meeting of Concurrent Technologies Plc will be held at the Company's offices at 4 Gilberd Court, Newcomen Way, Colchester, Essex, CO4 9WN, on 27 May 2014 at 2:30pm.

 

All companies and product names are trademarks of their respective organisations.

 

Consolidated Statement of Comprehensive Income

Year to

Year to

31 December

31 December

2013

2012

CONTINUING OPERATIONS

£

£

Revenue

11,859,180

12,794,380

Cost of sales

5,857,094

6,183,357

Gross profit

6,002,086

6,611,023

Operating expenses

5,614,290

4,666,346

Group operating profit

387,796

1,944,677

Finance income

66,133

56,727

Profit before tax

453,929

2,001,404

Tax

(275,688)

34,749

Profit for the year

729,617

1,966,655

Other Comprehensive Income

Items that will be reclassified subsequently to profit or loss:

Exchange differences on translating foreign operations

(124,637)

(131,051)

Tax relating to components of other comprehensive income

-

-

Other Comprehensive Income for the year, net of tax

(124,637)

(131,051)

Total Comprehensive Income for the year

604,980

1,835,604

Profit for the period attributable to:

Equity holders of the parent

729,617

1,966,655

Total Comprehensive Income attributable to:

Equity holders of the parent

604,980

1,835,604

Earnings per share

Basic earnings per share

1.02p

2.75p

Diluted earnings per share

1.01p

2.73p

 

Consolidated Balance Sheet

As at

As at

31 December

31 December

2013

2012

£

£

ASSETS

Non-current assets

Property, plant and equipment

478,131

437,851

Intangible assets

5,467,503

5,948,660

Deferred tax assets

108,396

188,323

Other financial assets

-

1,000,000

6,054,030

7,574,834

Current assets

Inventories

2,550,556

2,967,690

Trade and other receivables

2,874,354

3,274,665

Current tax assets

247,240

123,696

Other financial assets

2,602,689

1,000,000

Cash and cash equivalents

2,340,859

2,316,928

10,615,698

9,682,979

Total assets

16,669,728

17,257,813

LIABILITIES

Non-current liabilities

Deferred tax liabilities

1,164,267

1,404,686

Long term provisions

10,009

-

1,174,276

1,404,686

Current liabilities

Trade and other payables

1,931,110

1,511,755

Short term provisions

36,813

39,746

1,967,923

1,551,501

Total liabilities

3,142,199

2,956,187

Net assets

13,527,529

14,301,626

EQUITY

Capital and reserves

Share capital

727,000

727,000

Share premium account

3,405,817

3,405,817

Capital redemption reserve

256,976

256,976

Cumulative translation reserve

(74,816)

49,821

Profit and loss account

9,212,552

9,862,012

Equity attributable to equity holders of the parent

13,527,529

14,301,626

Total equity

13,527,529

14,301,626

 

Consolidated Cash Flow Statement

Year to

Year to

31 December

31 December

2013

2012

£

£

Cash flows from operating activities

Profit before tax for the period

453,929

2,001,404

Adjustments for:

Finance income

(66,133)

(56,727)

Depreciation

169,259

206,286

Amortisation

1,363,530

1,328,131

Impairment loss

842,783

236,733

Loss on disposal of property, plant and equipment (PPE)

-

5,714

Share-based payment

(94,726)

11,941

Exchange differences

(74,551)

(45,511)

(Increase) in inventories

417,134

(341,030)

(Increase)/decrease in trade and other receivables

400,311

(884,288)

Increase/(decrease) in trade and other payables

426,431

(230,060)

Cash generated from operations

3,837,967

2,232,593

Tax (paid)/received

(61,654)

19,622

Net cash generated from operating activities

3,776,313

2,252,215

Cash flows from investing activities

Interest received

66,133

56,727

Cash placed on Deposit

(602,689)

-

Purchases of property, plant and equipment (PPE)

(225,505)

(181,263)

Capitalisation of development costs and purchases of intangible assets

(1,726,312)

(2,136,090)

Net cash used in investing activities

(2,488,373)

(2,260,626)

Cash flows from financing activities

Equity dividends paid

(1,214,420)

(1,179,051)

Purchase of treasury shares

(16,625)

(17,038)

Net cash used in financing activities

(1,231,045)

(1,196,089)

Effects of exchange rate changes on cash and cash equivalents

(32,964)

(72,703)

Net increase/(decrease) in cash

23,931

(1,277,203)

Cash at beginning of period

2,316,928

3,594,131

Cash at the end of the period

2,340,859

2,316,928

 

Consolidated Statement of Changes in Equity

Capital

Cumulative

Profit

Share

Share

redemption

translation

and loss

Total

capital

premium

reserve

reserve

account

Equity

£

£

£

£

£

£

Balance at 1 January 2012

727,000

 3,405,817

256,976

180,872

9,052,951

13,623,616

Profit for the period

-

-

-

-

1,966,655

1,966,655

Exchange differences on translating foreign operations

-

-

-

(131,051)

-

(131,051)

Total comprehensive income for the period

-

-

-

(131,051)

1,966,655

1,835,604

Transactions with owners:

Share-based payment

-

-

-

-

11,941

11,941

Deferred tax on share based payment

-

-

-

-

26,554

26,554

Dividends paid

-

-

-

-

(1,179,051)

(1,179,051)

Purchase of treasury shares

-

-

-

-

(17,038)

(17,038)

Balance at 31 December 2012

727,000

 3,405,817

256,976

49,821

9,862,012

14,301,626

Profit for the period

-

-

-

-

729,617

729,617

Exchange differences on translating foreign operations

-

-

-

(124,637)

-

(124,637)

Total comprehensive income for the period

-

-

-

(124,637)

729,617

604,980

Transactions with owners:

Share-based payment

-

-

-

-

(94,726)

(94,726)

Deferred tax on share based payment

-

-

-

-

(53,306)

(53,306)

Dividends paid

-

-

-

-

(1,214,420)

(1,214,420)

Purchase of treasury shares

-

-

-

-

(16,625)

(16,625)

Balance at 31 December 2013

727,000

 3,405,817

256,976

(74,816)

9,212,552

13,527,529

 

NOTES

 

1. The financial information set out above does not constitute the Group's statutory accounts for the years ended 31 December 2013 or 2012, but is derived from those accounts. Statutory accounts for 2012 have been delivered to the Registrar of Companies and those for 2013 will be delivered following the Annual General Meeting. The auditors have reported on those accounts; their reports were (i) unqualified and (ii) did not contain statements under section 498(2) or (3) of the Companies Act 2006 in respect of 2012 or 2013.

 

2. The calculation of basic earnings per share is based on the weighted average number of Ordinary Shares in issue during 2013 of 71,430,298 (2012: 71,451,883) allowing for an adjustment made as a consequence of the Company having purchased at various times during the year 40,000 (2012: 45,000) Ordinary Shares and on the profit after tax for 2013 of £729,617 (2012: £1,966,655). The calculation of diluted earnings per share incorporates 593,207 Ordinary Shares (2012: 534,454) in respect of performance related employee share options. The profit after tax is the same as for basic earnings per share.

 

3. The annual general meeting of Concurrent Technologies Plc will be held at the Company's offices at 4 Gilberd Court, Newcomen Way, Colchester, Essex, CO4 9WN, on 27 May 2014 at 2:30pm.

 

Copies of the Annual Report will be sent to Shareholders and will also be available from the Company's Registered Office: 4, Gilberd Court, Newcomen Way, Colchester, Essex, CO4 9WN, UK, and on the Company's website: www.cct.co.uk.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FR EAXDLAFNLEFF
Date   Source Headline
13th May 20134:25 pmRNSProduct Launch
24th Apr 20135:01 pmRNSDistribution of Annual Report and Accounts
9th Apr 20137:00 amRNSFinal Results
19th Mar 20134:25 pmRNSNotice of Results & Dividend
1st Mar 20132:15 pmRNSProduct Launch
24th Dec 20127:00 amRNSTrading Update
21st Dec 20121:17 pmRNSProduct Launch
21st Nov 20123:27 pmRNSHolding(s) in Company
5th Nov 201212:25 pmRNSProduct Launch
31st Oct 201210:32 amRNSTotal Voting Rights
19th Sep 20125:28 pmRNSHolding(s) in Company
5th Sep 20127:00 amRNSInterim Results
29th Aug 20125:36 pmRNSNotice of Results
22nd Jun 20124:42 pmRNSTotal Voting Rights
14th Jun 20123:50 pmRNSTransaction in Own Shares
7th Jun 20127:00 amRNSProduct Launch
31st May 20123:30 pmRNSTotal Voting Rights
29th May 20121:30 pmRNSAGM Statement
22nd May 201212:21 pmRNSTreasury Shares
8th May 20127:00 amRNSDistribution of Annual Report and Accounts
4th May 20123:53 pmRNSHolding(s) in Company
17th Apr 20123:51 pmRNSHolding(s) in Company
12th Apr 201211:44 amRNSHolding(s) in Company
26th Mar 20127:00 amRNSPreliminary Results
16th Mar 20123:17 pmRNSNotice of Results
6th Mar 20121:45 pmRNSDividend Declaration
16th Jan 20127:00 amRNSProduct Launch
29th Dec 20115:46 pmRNSDirector/PDMR Shareholding
22nd Dec 201112:41 pmRNSTrading Statement
9th Dec 20114:53 pmRNSProduct Launch
2nd Dec 201111:03 amRNSProduct Launch
13th Sep 201110:30 amRNSDirector/PDMR Shareholding
1st Sep 20117:00 amRNSInterim Results
25th Aug 20115:00 pmRNSNotice of Interim Results
29th Jul 20113:24 pmRNSTotal Voting Rights
30th Jun 201112:16 pmRNSTotal Voting Rights
25th May 20114:09 pmRNSHolding(s) in Company
20th May 20111:33 pmRNSAGM Statement
27th Apr 20117:00 amRNSDistribution of Annual Report & Accounts
26th Apr 20112:54 pmRNSTotal Voting Rights
25th Mar 20117:00 amPRNFinal Results
18th Mar 201111:34 amRNSNotice of Results
11th Mar 201112:13 pmRNSDividend Declaration
3rd Mar 20111:40 pmRNSHolding(s) in Company
31st Jan 201111:14 amRNSHolding(s) in Company
6th Jan 201110:38 amRNSHolding(s) in Company
6th Jan 20117:00 amRNSProduct Launch
24th Dec 201011:55 amRNSTotal Voting Rights
22nd Dec 20107:00 amRNSTrading Statement
17th Dec 20103:45 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.